- Licensed anti-HIV drugs
- Discontinued anti-HIV drugs
- Experimental anti-HIV drugs and treatments
- Herbal and naturopathic treatments
- Failed anti-HIV drugs
- 935U83
- A-74704, A-77003 & A-80987
- AL-721
- ALX40-4C
- AMD3100
- Aplaviroc
- Ampligen
- Atevirdine
- Aztec
- BB-10010
- Butyl DNJ
- Capravirine
- Castanospermine
- Compound Q
- DAPD
- DFC (dexelvucitabine)
- DMP-450
- dOTC
- DPC 083
- DPC 681 and DPC 684
- DPC 961 and DPC 963
- Emivirine
- FLT
- GEM 92
- GW420867X
- KNI-272
- L-697,661
- Lithium gamma-linolenate
- Lodenosine
- Loviride
- Oxpentifylline
- Quinotaline
- RO033-4649
- Ro 24-7429
- SC-52151 & SC-55389A
- SID791
- SPC3
Failed anti-HIV drugs
- 935U83
- A-74704, A-77003 & A-80987
- AL-721
- ALX40-4C
- AMD3100
- Aplaviroc
- Ampligen
- Atevirdine
- Aztec
- BB-10010
- Butyl DNJ
- Capravirine
- Castanospermine
- Compound Q
- DAPD
- DFC (dexelvucitabine)
- DMP-450
- dOTC
- DPC 083
- DPC 681 and DPC 684
- DPC 961 and DPC 963
- Emivirine
- FLT
- GEM 92
- GW420867X
- KNI-272
- L-697,661
- Lithium gamma-linolenate
- Lodenosine
- Loviride
- Oxpentifylline
- Quinotaline
- RO033-4649
- Ro 24-7429
- SC-52151 & SC-55389A
- SID791
- SPC3
latest aidsmap news
- Unsuccessful post-exposure prophylaxis may still result in weaker HIV infection and lower viral load
- Jury still out on whether circumcision protects gay men against HIV
- Antiretroviral therapy does not fully reverse impact of HIV on hepatitis C-related cirrhosis
- High early mortality after starting antiretroviral treatment in Africa
- Nobel prize awarded to French discoverers of HIV
- Fall in number of undiagnosed HIV infections in the US
- Resistance to darunavir related to pre-existing mutations
- Higher levels of drug resistance seen after first-line NNRTI failure than boosted PI failure: meta-analysis
- Wide variation found in anal HPV viral loads in HIV-positive men
- Offering rapid point-of-care tests would increase uptake of HIV testing